Published in Am J Clin Nutr on August 01, 2007
High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology (2010) 4.11
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol (2010) 2.50
Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab (2012) 1.68
Rodent models for metabolic syndrome research. J Biomed Biotechnol (2010) 1.53
A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia (2008) 1.49
Nonalcoholic fatty liver disease. J Lipid Res (2008) 1.47
Toward a unifying hypothesis of metabolic syndrome. Pediatrics (2012) 1.36
Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol (2014) 1.30
Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS One (2012) 1.19
Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism (2010) 1.15
Effect of anaplerotic fluxes and amino acid availability on hepatic lipoapoptosis. J Biol Chem (2009) 1.15
Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch (2011) 1.07
Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr (2014) 1.05
Dietary fructose and glucose differentially affect lipid and glucose homeostasis. J Nutr (2009) 1.02
Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner? World J Gastroenterol (2014) 1.01
Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol (2014) 1.01
Predicting the impact of diet and enzymopathies on human small intestinal epithelial cells. Hum Mol Genet (2013) 0.99
Design and methods for testing a simple dietary message to improve weight loss and dietary quality. BMC Med Res Methodol (2009) 0.98
Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J Gastroenterol (2012) 0.96
Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. J Clin Endocrinol Metab (2015) 0.96
Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and IL-6 levels in patients with NAFLD: a pilot study. J Gastroenterol (2011) 0.95
Bofutsushosan, an Oriental Herbal Medicine, Attenuates the Weight Gain of White Adipose Tissue and the Increased Size of Adipocytes Associated with the Increase in Their Expression of Uncoupling Protein 1 in High-Fat Diet-Fed Male KK/Ta mice. J Clin Biochem Nutr (2008) 0.94
Blood-Based Indicators of Insulin Resistance and Metabolic Syndrome in Bottlenose Dolphins (Tursiops truncatus). Front Endocrinol (Lausanne) (2013) 0.94
Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLoS One (2014) 0.92
Remodeling of lipid metabolism by dietary restriction of essential amino acids. Diabetes (2013) 0.92
Plasma free myristic acid proportion is a predictor of nonalcoholic steatohepatitis. Dig Dis Sci (2011) 0.92
Lipotoxicity: effects of dietary saturated and transfatty acids. Mediators Inflamm (2013) 0.91
Access to healthy food stores modifies effect of a dietary intervention. Am J Prev Med (2014) 0.91
[Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe (2010) 0.90
Dietary Quality Indices and Biochemical Parameters Among Patients With Non Alcoholic Fatty Liver Disease (NAFLD). Hepat Mon (2013) 0.90
Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients (2013) 0.89
Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br J Nutr (2012) 0.88
How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease? Hepat Mon (2013) 0.88
Metabolomic changes in fatty liver can be modified by dietary protein and calcium during energy restriction. World J Gastroenterol (2008) 0.88
Single-component versus multicomponent dietary goals for the metabolic syndrome: a randomized trial. Ann Intern Med (2015) 0.87
Dietary recommendations for patients with nonalcoholic fatty liver disease. Prz Gastroenterol (2014) 0.86
Dietary conjugated linoleic Acid and hepatic steatosis: species-specific effects on liver and adipose lipid metabolism and gene expression. J Nutr Metab (2011) 0.85
Dietary patterns in Brazilian patients with nonalcoholic fatty liver disease: a cross-sectional study. Clinics (Sao Paulo) (2013) 0.83
Effect of Vitamin D Supplementation on C-reactive Protein in Patients with Nonalcoholic Fatty Liver. Int J Prev Med (2014) 0.83
Hepatic Steatosis, Carbohydrate Intake, and Food Quotient in Patients with NAFLD. Int J Endocrinol (2013) 0.82
Pathophysiology guided treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol (2012) 0.82
The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci (2015) 0.82
Genome-based nutrition: an intervention strategy for the prevention and treatment of obesity and nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.81
Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis. PLoS One (2015) 0.81
Amelioration of diet-induced nonalcoholic steatohepatitis in rats by Mn-salen complexes via reduction of oxidative stress. J Biomed Sci (2012) 0.81
Evaluation of dietary effects on hepatic lipids in high fat and placebo diet fed rats by in vivo MRS and LC-MS techniques. PLoS One (2014) 0.80
Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage. Dig Dis Sci (2011) 0.79
Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease. J Diabetes Res (2015) 0.79
[Steatohepatitis after chemotherapy for colorectal liver metastases (CASH)]. Pathologe (2011) 0.79
Medical nutrition therapy in non-alcoholic fatty liver disease--a review of literature. J Med Life (2015) 0.78
Comparing the effects of nano-sized sugarcane fiber with cellulose and psyllium on hepatic cellular signaling in mice. Int J Nanomedicine (2012) 0.78
Metabolic responses to dietary leucine restriction involve remodeling of adipose tissue and enhanced hepatic insulin signaling. Biofactors (2015) 0.78
Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol (2011) 0.78
Current status of therapy in nonalcoholic Fatty liver disease. Therap Adv Gastroenterol (2009) 0.78
Data from a randomized and controlled trial of LCarnitine prescription for the treatment for Non- Alcoholic Fatty Liver Disease. Bioinformation (2014) 0.78
Is there an effective therapy available for non-alcoholic fatty liver disease? F1000 Med Rep (2009) 0.77
The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. Int J Prev Med (2016) 0.77
Treatment options for nonalcoholic Fatty liver disease. Therap Adv Gastroenterol (2008) 0.77
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract (2016) 0.77
A High-Fat, High-Fructose Diet Induces Antioxidant Imbalance and Increases the Risk and Progression of Nonalcoholic Fatty Liver Disease in Mice. Scientifica (Cairo) (2016) 0.77
Dietary walnut oil modulates liver steatosis in the obese Zucker rat. Eur J Nutr (2013) 0.77
Role of transcription factor acetylation in the regulation of metabolic homeostasis. Protein Cell (2015) 0.76
Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents. Hepat Mon (2014) 0.76
Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J (2015) 0.76
A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol. BMC Gastroenterol (2016) 0.76
Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Adv Biomed Res (2016) 0.76
Time-dependent behavioral, neurochemical, and metabolic dysregulation in female C57BL/6 mice caused by chronic high-fat diet intake. Physiol Behav (2016) 0.76
Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Gastroenterol Res Pract (2016) 0.76
Insulin resistance in clinical and experimental alcoholic liver disease. Ann N Y Acad Sci (2015) 0.75
Associations between Dietary Nutrient Intakes and Hepatic Lipid Contents in NAFLD Patients Quantified by ¹H-MRS and Dual-Echo MRI. Nutrients (2016) 0.75
Are miRNA-103, miRNA-107 and miRNA-122 Involved in the Prevention of Liver Steatosis Induced by Resveratrol? Nutrients (2017) 0.75
Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol (2017) 0.75
Effect of soy protein supplementation in patients with chronic hepatitis C: a randomized clinical trial. World J Gastroenterol (2012) 0.75
Non-alcoholic fatty liver disease in a patient with maturity onset diabetes in the young. BMJ Case Rep (2009) 0.75
CD36 genetic variation, fat intake and liver fibrosis in chronic hepatitis C virus infection. World J Hepatol (2016) 0.75
Pilot study for an age- and gender-based nutrient signaling system for weight control. Age (Dordr) (2008) 0.75
Association of patatin-like phospholipase domain-containing protein 3 gene polymorphisms with susceptibility of nonalcoholic fatty liver disease in a Han Chinese population. Medicine (Baltimore) (2016) 0.75
Animal models of metabolic syndrome: a review. Nutr Metab (Lond) (2016) 0.75
Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. Nutrients (2017) 0.75
Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery. BMC Obes (2017) 0.75
A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci (2017) 0.75
Lack of Additive Effects of Resveratrol and Energy Restriction in the Treatment of Hepatic Steatosis in Rats. Nutrients (2017) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
The genome sequence of taurine cattle: a window to ruminant biology and evolution. Science (2009) 8.23
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol (2013) 3.51
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology (2004) 3.45
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Metabolomics: building on a century of biochemistry to guide human health. Metabolomics (2005) 3.01
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Sepsis-induced cholestasis. Hepatology (2007) 2.80
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
A strategy for annotating the human milk glycome. J Agric Food Chem (2006) 2.42
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
Human milk glycobiome and its impact on the infant gastrointestinal microbiota. Proc Natl Acad Sci U S A (2010) 2.34
Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific, preferential consumption of small chain glycans secreted in early human lactation. J Agric Food Chem (2007) 2.33
Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res (2002) 2.30
In vitro fermentation of breast milk oligosaccharides by Bifidobacterium infantis and Lactobacillus gasseri. Appl Environ Microbiol (2006) 2.21
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology (2009) 2.16
Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology (2008) 2.10
Consumption of human milk oligosaccharides by gut-related microbes. J Agric Food Chem (2010) 2.07
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Development of an annotated library of neutral human milk oligosaccharides. J Proteome Res (2010) 1.99
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab (2012) 1.97
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective. Am J Gastroenterol (2009) 1.93
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (2013) 1.92
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology (2007) 1.90
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol (2007) 1.87
Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology (2012) 1.86
MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl (2007) 1.86
Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol (2011) 1.85
A quantitative and comprehensive method to analyze human milk oligosaccharide structures in the urine and feces of infants. Anal Bioanal Chem (2013) 1.83
The bovine lactation genome: insights into the evolution of mammalian milk. Genome Biol (2009) 1.77
Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways. Cell Host Microbe (2011) 1.77
Cirrhotic cardiomyopathy. J Am Coll Cardiol (2010) 1.77
Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int (2009) 1.76
Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl (2004) 1.76
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Annotation and structural analysis of sialylated human milk oligosaccharides. J Proteome Res (2011) 1.68
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol (2012) 1.61
Portal hypertensive bleeding. Gastroenterol Clin North Am (2003) 1.60
Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int (2009) 1.59
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology (2010) 1.58
Do trans fatty acids from industrially produced sources and from natural sources have the same effect on cardiovascular disease risk factors in healthy subjects? Results of the trans Fatty Acids Collaboration (TRANSFACT) study. Am J Clin Nutr (2008) 1.57
Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology (2010) 1.55
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol (2010) 1.52
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One (2013) 1.51
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology (2006) 1.50
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials (2009) 1.48
In vitro fermentability of human milk oligosaccharides by several strains of bifidobacteria. Mol Nutr Food Res (2007) 1.46
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl (2011) 1.44
Recurrent variceal bleeding despite endoscopic and medical therapy. Gastroenterology (2004) 1.39
Daily variations in oligosaccharides of human milk determined by microfluidic chips and mass spectrometry. J Agric Food Chem (2007) 1.39
A versatile and scalable strategy for glycoprofiling bifidobacterial consumption of human milk oligosaccharides. Microb Biotechnol (2008) 1.38
Ascites: diagnosis and management. Med Clin North Am (2009) 1.37
Drug-induced steatohepatitis. Clin Liver Dis (2003) 1.36
A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol (2004) 1.33
The influence of milk oligosaccharides on microbiota of infants: opportunities for formulas. Annu Rev Food Sci Technol (2011) 1.30
Endoplasmic reticulum stress and the unfolded protein response. Clin Liver Dis (2009) 1.28
Oligosaccharide binding proteins from Bifidobacterium longum subsp. infantis reveal a preference for host glycans. PLoS One (2011) 1.25
Extensive in vivo human milk peptidomics reveals specific proteolysis yielding protective antimicrobial peptides. J Proteome Res (2013) 1.25
An infant-associated bacterial commensal utilizes breast milk sialyloligosaccharides. J Biol Chem (2011) 1.25
Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology (2008) 1.24
Lacto-N-tetraose, fucosylation, and secretor status are highly variable in human milk oligosaccharides from women delivering preterm. J Proteome Res (2012) 1.23
Toward the implementation of metabolomic assessments of human health and nutrition. Curr Opin Biotechnol (2002) 1.23
Gene regulatory networks in lactation: identification of global principles using bioinformatics. BMC Syst Biol (2007) 1.23
Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis (2004) 1.22
Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol (2009) 1.21
Applications of metabolomics in agriculture. J Agric Food Chem (2006) 1.20
Portal hypertension and variceal hemorrhage. Med Clin North Am (2008) 1.19
Breast milk oligosaccharides: structure-function relationships in the neonate. Annu Rev Nutr (2014) 1.19
Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol (2010) 1.17
The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol (2002) 1.16
The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol (2002) 1.16
Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis (2004) 1.15
HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology (2009) 1.15
Comparison of the human and bovine milk N-glycome via high-performance microfluidic chip liquid chromatography and tandem mass spectrometry. J Proteome Res (2012) 1.15
Endo-β-N-acetylglucosaminidases from infant gut-associated bifidobacteria release complex N-glycans from human milk glycoproteins. Mol Cell Proteomics (2012) 1.14
Comprehensive profiles of human milk oligosaccharides yield highly sensitive and specific markers for determining secretor status in lactating mothers. J Proteome Res (2012) 1.13
Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol (2009) 1.13
Human milk glycomics and gut microbial genomics in infant feces show a correlation between human milk oligosaccharides and gut microbiota: a proof-of-concept study. J Proteome Res (2014) 1.12
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Permeate from cheese whey ultrafiltration is a source of milk oligosaccharides. Int Dairy J (2009) 1.12
Methods for the quantitation of human milk oligosaccharides in bacterial fermentation by mass spectrometry. Anal Biochem (2006) 1.11